Key takeaways:
Both Mounjaro (tirzepatide) and metformin are FDA approved to treat Type 2 diabetes. Mounjaro is a weekly injection approved for adults. Metformin is an oral medication approved for people as young as age 10.
Mounjaro provides better blood sugar (glucose) management and more potential weight loss than metformin. But metformin is often more cost-effective for many people. If needed, you can use Mounjaro and metformin together.
Mounjaro and metformin both can cause similar stomach-related side effects, such as nausea and diarrhea. Mounjaro also has been linked to pancreatitis and gallbladder disease, while metformin carries a rare risk of lactic acidosis.
Mounjaro and metformin are both available as brand-name medications. But you can also find metformin as a lower-cost generic. GoodRx can help make your prescription more affordable.
Save on related medications
The oral medication metformin has been a mainstay when it comes to treating Type 2 diabetes for decades. But in recent years, several injectable medications, such as Mounjaro (tirzepatide), have entered the playing field. This has left many people wondering if these new medications are a better choice.
Both Mounjaro and metformin can be effective treatments. But, while they both lower blood sugar (glucose), they do it in different ways. And there are differences when it comes to potential weight loss, dosages, and side effects, too. Some of these distinctions may determine why a healthcare professional prescribes one over the other.
Let’s be clear — the “best” diabetes medication is different for everyone. But it never hurts to review your options with your prescriber. Here are nine differences between Mounjaro and metformin, and times when one might be a better option.
1. Metformin is a more common first-choice diabetes medication than Mounjaro
Metformin remains the go-to choice for many healthcare professionals when prescribing a Type 2 diabetes medication. And for good reason — it works and is cost-effective.
Metformin effectively lowers hemoglobin A1C (HbA1C or A1C). Your A1C represents your average blood sugar over the past 3 months. Metformin may also help lower the risk of heart-related problems, such as heart attacks. What’s more, there are lower-cost generic versions available.
Mounjaro also helps lower A1C. But whether it has heart-related benefits is still being studied. And it’s currently available only as a brand-name medication. Where Mounjaro really stands out from metformin is its potential weight loss benefit (more details on this below).
Your prescriber will take multiple factors into account when selecting the right diabetes medication for you. But if weight management is part of your diabetes treatment plan, your prescriber may recommend Mounjaro.
2. Mounjaro and metformin work differently to lower blood glucose
Mounjaro belongs to a group of medications with a very long name: dual glucose-dependent insulinotropic polypeptide (GIP)/glucagon-like peptide-1 (GLP-1) agonists. It acts like GIP and GLP-1, two gut hormones found naturally in the body. These hormones play a role in digestion, appetite, and blood sugar regulation.
Mounjaro signals the pancreas to release insulin after eating. It also stops your liver from making extra sugar and slows the passage of food through the gut. These actions help lower blood sugar. Mounjaro is also thought to target areas of the brain that regulate appetite and fullness, which can contribute to its weight loss benefits.
Can you use both? Experts explain when you might use Mounjaro (tirzepatide) and metformin together.
Experts tips: Your hemoglobin A1C (HbA1c or A1C) helps determine your diabetes management plan. Here, experts review proven tips for lowering your A1C to help you meet your treatment goals.
What to expect: Three people describe their experiences with starting treatment with Mounjaro and how they managed side effects.
Metformin is a biguanide. Similarly to Mounjaro, it lowers the amount of sugar your liver makes. But that’s where the similarities stop when it comes to how they work. Metformin doesn’t tell your pancreas to release insulin. Instead, it makes your body more sensitive to the insulin you make naturally. It also lowers the amount of sugar you absorb from the food you eat.
For some people, either Mounjaro or metformin work well enough by themselves. But because they work in two different ways, they can be combined for additional blood sugar improvement. So it’s possible you could take both Mounjaro and metformin.
3. Mounjaro and metformin have different dosages and dosage forms
How you use Mounjaro and metformin is one of the most obvious differences between them. Mounjaro comes as a once-weekly injection. Metformin is an oral medication that comes in pill and liquid forms. It’s usually taken once or twice a day.
- GlucophageMetformin
- RiometMetformin
- Glucophage XRMetformin ER (Glucophage XR)
This difference in dosage forms can sometimes be a deciding factor. Mounjaro can be more convenient, since you take it only once a week. But some people may be nervous about giving themselves a shot. For them, an oral medication such as metformin may be easier.
Be sure to discuss your preferences with your healthcare team. No matter which you use, Mounjaro and metformin work best when you use them consistently. For this reason, it’s important that your prescriber knows if a certain dosage form is a better fit for your lifestyle.
4. Mounjaro may provide greater A1C reduction than metformin
Both Mounjaro and metformin are good at lowering A1C. The two medications haven’t been directly compared to each other in studies. But individual study data suggests that Mounjaro may provide better A1C reduction than metformin.
In initial clinical trials, Mounjaro lowered A1C by about 2% on average. Additionally, about 90% of study participants were able to get their A1C under 7% (a typical goal for many people with Type 2 diabetes). On the flip side, metformin typically provides an average A1C reduction of 1% to 1.5%.
So while both work well, Mounjaro may work a little bit better.
5. Mounjaro can result in greater weight loss than metformin
Mounjaro’s weight loss potential is often the reason it makes headlines. In fact, it’s so effective when it comes to weight loss that the FDA has approved it for this use under the brand name Zepbound.
Of the current diabetes medications available, Mounjaro appears to provide the greatest body weight reduction. In clinical trials, people with Type 2 diabetes and a larger body size experienced an average of about a 15% reduction in body weight with the highest dose of Mounjaro.
Metformin, on the other hand, is considered a “weight-neutral” diabetes medication. It may not cause body weight changes for most people who take it. But for some people, it can provide a modest weight loss. In some studies, people taking metformin for a year have noted up to a 6 lb weight loss.
6. Metformin is approved for use in children, but Mounjaro is approved only for adults
Metformin is FDA approved for Type 2 diabetes in both adults and children. In fact, it can be given to kids as young as age 10. It’s one of a few oral diabetes medications approved for kids. But it tends to be the treatment of choice for most children with Type 2 diabetes.
Mounjaro is currently approved only for use in adults. There is a completed clinical trial that studied its safety and effectiveness in children ages 10 and older. The results have not been announced or published yet. But it’s possible Mounjaro may be approved for kids in the near future.
7. Mounjaro and metformin have unique risks
Mounjaro and metformin share some common side effects. Both tend to cause gastrointestinal side effects for many people. This is especially true when you start treatment or shortly after raising the dose.
Common side effects of both Mounjaro and metformin include:
Nausea
Diarrhea
Vomiting
Stomach pain or discomfort
Both Mounjaro and metformin have a low risk of low blood sugar (hypoglycemia). This risk goes up if you’re also taking insulin or medications that cause your body to release insulin. These include sulfonylureas, such as glipizide, and glinides, such as repaglinide.
When taken long term, metformin can lower vitamin B-12 levels. This can lead to anemia (low red blood cells). Metformin also has a risk of lactic acidosis. This side effect is extremely rare but can be life-threatening.
In comparison, Mounjaro has been linked to pancreatitis (inflammation of the pancreas) and gallbladder disease. Animal studies also found that Mounjaro raised the risk of a certain type of thyroid cancer. But human studies haven’t found this same link. If you have a history of these conditions, Mounjaro might not be right for you.
These aren’t the only possible side effects for either Mounjaro or metformin. Please discuss the risks of these medications with your prescriber and pharmacist for more details.
8. Metformin is available in combination pills with other diabetes medications
There are many combination diabetes medications available. Since it’s prescribed so frequently, metformin is a common medication included in these combination pills. These products can help lower the number of pills you take in a day. This can make it easier to remember your pills and stick to your medication regimen.
Examples of combination pills that include metformin include:
Janumet and Janumet XR (sitagliptin / metformin)
Synjardy and Synjardy XR (empagliflozin / metformin)
Jentadueto and Jentadueto XR (linagliptin / metformin)
Mounjaro’s active ingredient, tirzepatide, isn’t included in any combination products right now. But given that Mounjaro is newer compared with metformin, this could change.
9. Metformin is available as a lower-cost generic, and Mounjaro is a brand-name medication only
When it comes to treating Type 2 diabetes, cost is often a focus. Costs quickly add up, between medications, supplies for checking blood sugar, appointments, and more. So it’s not surprising that people want to get the best price on their prescriptions whenever they can.
One of the best ways to save on your prescriptions is to fill a generic version of a medication, when one is available. Metformin has been on the market for a while. And most dosage forms have a generic version. Mounjaro is available only as a brand-name medication right now.
This difference can affect your prescription costs. Insurance plans often cover generic medications with a lower copay. And they may require extra steps, such as a prior authorization, before they cover brand-name medications.
Can you use Mounjaro and metformin together?
Yes, it’s possible to use both Mounjaro and metformin together. This combination is recommended by experts if one of them isn’t working well enough on its own. But not everyone with Type 2 diabetes needs to take both. Your prescriber can help you decide if using both Mounjaro and metformin is a good option for you.
How to save on Mounjaro and metformin
There are many ways to save on Mounjaro and metformin. Both are available as brand-name medications. But you can also find metformin as a lower-cost generic. GoodRx can help you navigate many ways to save on your prescription.
Save with GoodRx. GoodRx can help you save over 90% off the average retail price of metformin. Its price at certain pharmacies is as low as $9.00 with a free GoodRx discount.
Save with a copay savings card. If you have commercial insurance and meet eligibility requirements, you could pay as little as $25 for Mounjaro with a copay savings card from the manufacturer.
The bottom line
Mounjaro (tirzepatide) and metformin both work well for treating Type 2 diabetes. Mounjaro is a once-weekly injection and is FDA approved for adults. Metformin comes as a once- or twice-daily oral medication that’s approved for adults and children as young as age 10.
Metformin is the starting treatment of choice for many people with Type 2 diabetes. But Mounjaro may be preferable if weight management is part of your diabetes treatment plan. Mounjaro and metformin can be prescribed together if neither is working well enough on its own.
There are many factors to consider when deciding between two diabetes medications. Your prescriber will take your health history, personal preferences, and insurance coverage into account. Be sure to discuss both options with your prescriber to see which one might be a better fit.
Why trust our experts?


References
American Diabetes Association. (n.d.). Figure 9.3 use of glucose-lowering medications in the management of type 2 diabetes. Diabetes.
American Diabetes Association. (n.d.). Table 9.2 features of medications for lowering glucose in type 2 diabetes. Diabetes.
American Diabetes Association. (n.d.). What is the A1C test?
American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes—2025. Diabetes Care.
American Diabetes Association Professional Practice Committee. (2024). 14. Children and adolescents: Standards of care in diabetes—2025. Diabetes Care.
Bezin, J., et al. (2022). GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care.
ClinicalTrials.gov. (2025). A study to evaluate tirzepatide (LY3298176) in pediatric and adolescent participants with type 2 diabetes mellitus inadequately controlled with metformin or basal insulin or both (SURPASS-PEDS). National Library of Medicine.
Eli Lilly and Company. (2022). FDA approves Lilly's Mounjaro (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.
Eli Lilly and Company. (2023). Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2.
Eli Lilly and Company. (2025). Mounjaro- tirzepatide injection, solution [package insert]. DailyMed.
Kamrul-Hasan, A. B. M., et al. (2025). Tirzepatide and cancer risk in individuals with and without diabetes: A systematic review and meta-analysis. Endocrinology and Metabolism.
Li, J. Z., et al. (2023). Cardiovascular protection by metformin: Latest advances in basic and clinical research. Cardiology.
Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial. The Lancet.
Sanchez-Rangel, E., et al. (2017). Metformin: Clinical use in type 2 diabetes. Diabetologia.
Time Cap Laboratories. (2025). Metformin HCL tablet, film coated [package insert]. DailyMed.
U.S. Food and Drug Administration. (2023). FDA approves new class of medicines to treat pediatric type 2 diabetes.









